NVO - Eli Lilly wins favorable terms for obesity drug use in U.K.
2024-06-04 14:57:26 ET
More on Eli Lilly, Novo Nordisk, etc.
- Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript)
- Eli Lilly's Growth And Challenges: A Cautious Buy
- Novo Nordisk: The Market Is Right, Don't Fight Against It
- Eli Lilly sees improving availability of GLP-1 drugs Mounjaro and Zepbound
- Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases